PC
ALDX icon

PA Capital’s Aldeyra Therapeutics ALDX Stock Holding History

PA Capital’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$576K Sell
77,727
-27,199
-26% -$176K 0.4% 93
2020
Q2 		$438K Sell
104,926
-32,304
-24% -$118K 0.32% 107
2020
Q1 		$339K Buy
137,230
+48,916
+55% +$220K 0.3% 111
2019
Q4 		$513K Buy
88,314
+39,812
+82% +$230K 0.45% 84
2019
Q3 		$256K Buy
48,502
+8,232
+20% +$44.3K 0.25% 104
2019
Q2 		$242K Buy
40,270
+7,211
+22% +$54.3K 0.22% 92
2019
Q1 		$299K Buy
33,059
+11,020
+50% +$93.6K 0.27% 89
2018
Q4 		$183K Buy
+22,039
New +$226K 0.19% 97

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

PA Capital's ALDX Position: Q3 2020 in Review

PA Capital reduced its Aldeyra Therapeutics (ALDX) stake by 26% in Q3 2020, selling an estimated $176K and leaving 77,727 shares worth $576K. The position accounts for 0.4% of the portfolio, ranked #93.

PA Capital first reported a position in ALDX in Q4 2018 and has held it in 8 quarters since. 87 funds tracked by Wall St. Rank hold ALDX as of Q3 2020.

  • PA Capital held 77,727 shares of Aldeyra Therapeutics worth $576K as of Q3 2020.
  • PA Capital sold 27,199 Aldeyra Therapeutics shares in Q3 2020, an estimated $176K.
  • Aldeyra Therapeutics made up 0.4% of PA Capital's portfolio in Q3 2020, its #93 holding.
  • PA Capital first reported a position in Aldeyra Therapeutics in Q4 2018 and has held it in 8 quarters since.
  • 87 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.